

Biography
Professional Summary
Professional Education
- Board Certification: American Board of Psychiatry and Neurology, Neurology (1994)
- Residency: University of Washington Medical Center (1993) WA
- Medical Education: Temple University School of Medicine (1989) PA
- B.A., Haverford College, French Literature (1983)
- +, Institut d'Études Françaises, Avignon, France (1982)
Honors & Awards
- "America's Top Rated Physicians", Guide to Top Doctors (1998-2007 inclusive)
- A. B. Baker National Teacher of the Year Recognition Award, American Academy of Neurology (2019)
- Arthur L. Bloomfield Award in Recognition of Excellence in Teaching Clinical Medicine, Stanford University School of Medicine (2017)
- Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)
- AUPN Neurology highest percentage National Recruitment Award, Association of University Professors of Neurology (2012, 2011)
- Excellence in Neurology Clerkship Teaching Award, Stanford University Neurology (2008-2017 inclusive)
- Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)
- Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)
- Excellence in Teaching Award, Stanford University School of Medicine (2011-2012)
- Fellow, American Academy of Neurology (2008-present)
- Healthcare Partner of the Year, National Multiple Sclerosis Society, NorCal (2019)
- Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, Stanford University School of Medicine (2013)
- Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences (2008-2009)
- Neurology Clerkship Teaching Award, Stanford University Neurology (2019-2020)
- Oscar Salvatierra Award for Exceptional Service to Medical Students and the School of Medicine, Stanford University School of Medicine (2021)
- Science Breakthrough of the Year, runner-up, American Association for the Advancement of Science (2022)
- Special Commendation for outstanding care, research and contributions to the MS community, California State Senate (2016)
- Top Doctors, Castle Connolly (2012-2021 inclusive)
Administrative Appointments
- Board Member, National Medical Advisory Committee, National Multiple Sclerosis Society (2018 - 2021)
- Chair, Multiple Sclerosis Section; American Academy of Neurology (2018 - 2020)
- Chief, Division of Neuroimmunology, Department of Neurology & Neurological Sciences (2009 - Present)
- Fellowship Director, Clinical Neuroimmunology Fellowship Program; Stanford University (2010 - 2017)
- Lily Sarafan Director of Neuroimmunology, Stanford University Department of Neurology (2022 - Present)
- Neurology Clerkship Director, Stanford University School of Medicine (2008 - 2019)
Publications
-
INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
Spach, D. H., Panther, L. A., Thorning, D. R., Dunn, J. E., Plorde, J. J., & MILLER, R. A. (1992). INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS. ANNALS OF INTERNAL MEDICINE, 116(9), 740–742. -
Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts
Pershing, S., Dunn, J., Khan, A., & Liao, Y. J. (2009). Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts. JOURNAL OF NEURO-OPHTHALMOLOGY, 29(3), 223–26. -
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., … Rose, J. W. (2010). Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. LANCET NEUROLOGY, 9(4), 381–390. -
Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
Dunn, J. (2010). Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 10(4), 433–40. -
Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis
Dunn, J., & Blight, A. (2011). Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. CURRENT MEDICAL RESEARCH AND OPINION, 27(7), 1415–23. -
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein
Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., Ko, R. M., … Axtell, R. C. (2012). Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. MULTIPLE SCLEROSIS JOURNAL, 18(4), 398–408. -
Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis. (2005). ECTRIMS/ACTRIMS, (September). -
Comprehensive Outpatient Management of Patients with Multiple Sclerosis
Comprehensive Outpatient Management of Patients with Multiple Sclerosis. (2001). RIMS MS Symposium, (May). -
Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV
Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV. (1992). Annals of Internal Medicine, 116. -
Atherosclerotic Aortic Disease as a Source of Embolic Infarct
Atherosclerotic Aortic Disease as a Source of Embolic Infarct. (1996). Journal of Neurovascular Disease, 1(2). -
Gingko Biloba in the Treatment of Alzheimer's Disease
Gingko Biloba in the Treatment of Alzheimer's Disease. (1998). Alternative Medicine, 1(15). -
Clinical Advisory Committee Statement
Clinical Advisory Committee Statement. (1999). Health Care Connection, I(1). -
Novantrone in the Treatment of Multiple Sclerosis
Novantrone in the Treatment of Multiple Sclerosis. (2001). Alliance News. -
Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis
Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis. (2008). Multiple Sclerosis, Apr 18. -
Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS
Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS. (2008). J Neurol, 255. -
Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS
Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS. (2007). Neurology, 68(12). -
Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II
Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II. (2007). ECTRIMS, 10/11/07. -
Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS
Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS. (2008). Multiple Sclerosis, 14. -
CMV Optic Neuritis with Extensive Tracking along the Visual Pathway
CMV Optic Neuritis with Extensive Tracking along the Visual Pathway. (2009). J Neuro-Ophthalmology, 29(3). -
Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis
Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis. (2011). Current Research Medical Opinion, 27(7). -
The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. (2010). Expert Rev. Pharmacoeconomics Outcomes Res., 10(4). -
Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein
Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein. (2012). Multiple Sclerosis, 18(4). -
Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis
Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. (2013). Annals of Neurology, 73(3). -
IFN-ß Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
Schubert, R. D., Hu, Y., Kumar, G., Szeto, S., Abraham, P., Winderl, J., … Axtell, R. C. (2015). IFN-ß Treatment Requires B Cells for Efficacy in Neuroautoimmunity. Journal of Immunology , 194(5), 2110–16. -
Disease modifying therapies for non relapsing Multiple Sclerosis
Dunn, J. (2013). Disease modifying therapies for non relapsing Multiple Sclerosis. Neurol Clin Pract, December(3). -
Mobility Concerns in Multiple Sclerosis
Lee, J.-mi, & Dunn, J. (2013). Mobility Concerns in Multiple Sclerosis. US Neurology, 9(1). -
Alemtuzumab for patients with relapsing Multiple Sclerosis after disease modifying therapy: a randomized controlled Phase 3 trial.
A, C. J., & CARE MS II, I. (2012). Alemtuzumab for patients with relapsing Multiple Sclerosis after disease modifying therapy: a randomized controlled Phase 3 trial. Lancet, Nov 24(380). -
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni, G., Cohen, J. A., Coles, A. J., Hartung, H.-P. P., Havrdova, E., Selmaj, K. W., … Compston, D. A. (2016). Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 87(19), 1985–1992. -
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., … Compston, D. A. S. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. LANCET, 380(9856), 1829–1839. -
Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis
Hauser, S. L., & OPERA Clinical Investigators. (2017). Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 376(3), 221–234. -
MRI CHARACTERISTICS OF CNS DEMYELINATING DISEASE IN ETHNIC INDIAN PATIENTS
Hua, L. H., Lee, J.-M., Dorfman, L., & Dunn, J. (2014). MRI CHARACTERISTICS OF CNS DEMYELINATING DISEASE IN ETHNIC INDIAN PATIENTS. MULTIPLE SCLEROSIS JOURNAL, 20(7), 920. -
Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24hiCD38hi Cells with Implications for the Diagnosis and Monitoring of MS
Schubert, R., Goodyear, A., Abraham, P., Dunn, C., Steinman, L., Dunn, J., & Axtell, R. (2013). Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24hiCD38hi Cells with Implications for the Diagnosis and Monitoring of MS. NEUROLOGY, 80. -
Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab
Carlson, A., Bozinov, N., Kipp, L., Dunn, J., & Lock, C. (2018). Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab. NEUROLOGY, 90. -
Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence.
Dunn, J. (2013). Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence. Neurology. Clinical Practice, 3(6), 515–18. -
The North American Registry for Care and Research in Multiple Sclerosis
Rammohan, K. W., Li, D., Halper, J., Murphy, S. M. C., Patton, L., Berger, J., … Thomas, F. P. (2019). The North American Registry for Care and Research in Multiple Sclerosis. MULTIPLE SCLEROSIS JOURNAL, 25, 79–80. -
Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management
Epstein, D. J., Dunn, J., & Deresinski, S. (2018). Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. OPEN FORUM INFECTIOUS DISEASES, 5(8). -
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore, W., Lund, B. T., Li, P., Levy, A. M., Kelland, E. E., Akbari, O., … Traboulsee, A. L. (2020). Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 17(1), 189. -
Defining the Neuroimmunology/Multiple Sclerosis Subspecialty: Surveys of Fellowship Training in the United States
Longbrake, E., Obeidat, A., Dunn, J., Sicotte, N., & Hua, L. (2020). Defining the Neuroimmunology/Multiple Sclerosis Subspecialty: Surveys of Fellowship Training in the United States. NEUROLOGY, 94(15). -
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.
Hua, L. H., Obeidat, A. Z., Amezcua, L., Cohen, J. A., Costello, K., Dunn, J., … Longbrake, E. E. (2021). Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology. Clinical Practice, 11(4), 352–357. -
Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S. S., Jude, K. M., Fernandez, D., … Robinson, W. H. (2022). Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Nature. -
KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19.
Li, J., Zaslavsky, M., Su, Y., Guo, J., Sikora, M. J., van Unen, V., … Davis, M. M. (2022). KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science (New York, N.Y.), eabi9591. -
Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL.
Gawde, S., Agasing, A., Bhatt, N., Toliver, M., Kumar, G., Massey, K., … Axtell, R. C. (2022). Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Multiple Sclerosis and Related Disorders, 63, 103922. -
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
Freedman, M. S., Pozzilli, C., Havrdova, E. K., Lemle, A., Burcklen, M., Larbalestier, A., … Olsson, T. (2022). Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies. Neurology. -
A case of MOG antibody disoorder with pontine involvement mimicking CLIPPERS and extensive transverse myelitis
Keroles, M., Stocksdale, B., Ng, J., Ahadi, S., & Dunn, J. (2022). A case of MOG antibody disoorder with pontine involvement mimicking CLIPPERS and extensive transverse myelitis. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis »
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab »
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two »
- Vitamin D Supplementation in Multiple Sclerosis »
- Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis »
Practice Locations
Multiple Sclerosis Center in Palo Alto Palo Alto, CA
Palo Alto, CAMultiple Sclerosis Center in Palo Alto
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Stanford Neuroscience Health Center Palo Alto, CA
Palo Alto, CAStanford Neuroscience Health Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Multiple Sclerosis Center Palo Alto, CA
Palo Alto, CAMultiple Sclerosis Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(249 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

- Send referrals online
- View referral status
- Access medical records